Bloom Burton analyst Prasath Pandurangan maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report) yesterday and set a price target of $19.50. The company's shares closed last Wednesday at $9.58, close to its 52-week low of $8.86. Pandurangan has an average return of 29.0% when recommending Aurinia Pharmaceuticals. According to TipRanks.com, Pandurangan is ranked #7412 out of 7861 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $24.06 average price target, which is an 118.3% upside from current levels.
https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-gets-a-buy-rating-from-bloom-burton?utm_source=advfn.com&utm_medium=referral
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Aurinia Pharmaceuticals Charts.
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Aurinia Pharmaceuticals Charts.